Table 2 Efficacy of a single dose of an oral chewable tablet containing sarolaner, moxidectin and pyrantel pamoate against induced ascarid infections in dogs
Study | Ascarid/Target stage (isolate origin) | Treatment groupa | n | Geometric mean worm count | Efficacy compared to placebo | |
|---|---|---|---|---|---|---|
% Efficacy | Test statistic | |||||
1 | Toxocara canis/immature adults (L5) (USA) | Placebo | 8 | 33.3 | – | – |
SAR + MOX + PYR | 8 | 1.6 | 95.2 | t(14) = 6.32 P < 0.0001 | ||
SAR + MOX | 8 | 8.4 | 74.7 | t(14) = 3.16 P = 0.0070 | ||
2 | Toxocara canis/immature adults (L5) (EU) | Placebo | 8 | 15.2 | – | – |
SAR + MOX + PYR | 8 | 0.3 | 97.9 | t(14) = 5.61 P = 0.0008 | ||
3 | Toxocara canis/adults (USA) | Placebo | 8 | 11.5 | – | – |
SAR + MOX + PYR | 8 | 0.1 | 99.2 | t(26) = 7.99 P < 0.0001 | ||
SAR | 8 | 7.3 | 36.7 | t(26) = 1.35 P = 0.1869 | ||
MOX | 8 | 0.8 | 92.8 | t(26) = 6.29 P < 0.0001 | ||
PYR | 8 | 0 | 100 | t(26) = 8.27 P < 0.0001 | ||
4 | Toxocara canis/adults (EU) | Placebo | 8 | 24.4 | – | – |
SAR + MOX + PYR | 8 | 0.6 | 97.3 | t(7) = 10.40 P = 0.0001 | ||
5 | Toxascaris leonina/adults (EU) | Placebo | 8 | 25.0 | – | – |
SAR + MOX + PYR | 8 | 2.6 | 89.7 | t(7) = 7.98 P < 0.0001 | ||
6 | Toxascaris leonina/adults (EU) | Placebo | 8 | 20.1 | – | – |
SAR + MOX + PYR | 8 | 0.1 | 99.6 | t(7) = 17. 02 P < 0.0001 | ||